Stay updated on Pembrolizumab in Neoplasms Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.

Latest updates to the Pembrolizumab in Neoplasms Clinical Trial page
- Check3 days agoChange DetectedMinor metadata updates were made, including a revision tag (v3.4.2) and update dates (2026-02-10, 2026-01-29, 2026-01). The government funding lapse notice was removed.SummaryDifference0.6%

- Check10 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and updated the revision to v3.4.1 (removing v3.4.0).SummaryDifference0.4%

- Check17 days agoChange DetectedGlossary display added; QC metadata updated to show Last Update Submitted that Met QC Criteria and Last Update Posted, with old QC labels replaced and Revision updated to v3.4.0.SummaryDifference0.3%

- Check32 days agoChange DetectedThe page's revision history shows an addition of 'Revision: v3.3.4' and a removal of 'Revision: v3.3.3'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedAdds a Locations section listing study sites in Illinois, Massachusetts, and Nebraska and updates the page revision to v3.3.3.SummaryDifference0.4%

- Check60 days agoChange DetectedStudy record dates were updated to include new entries (2025-12-12, 2025-11-19, 2026-03-01) and remove older ones (e.g., 2025-01-03, 2025-08-18, 2024-12-16), with a general update timestamp reflected as 'Last Update Posted'.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab in Neoplasms Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neoplasms Clinical Trial page.